The objective of this study was to investigate the riskfactors associated with the CYP1A1*2C [rs1048943: A>G] polymorphism in CML patientsand its role in therapeutic response to imatinib mesylate (IM) affecting clinico-pathologicalparameters, in the Indian population. Here, CYP1A1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.